Refixia

Description

Refixia is a purified recombinant human factor IX (rFIX) with a 40 kDa polyethylene glycol (PEG) protein conjugated. Patients with hemophilia B are deficient in clotting factor IX, which is essential for effective hemostasis. Administration of Refixia increases plasma levels of factor IX and may temporarily correct the coagulation defect in patients with hemophilia B. Factor IX is activated by factor XIa and the factor VII/tissue factor complex. When the drug is activated, the activation peptide, which includes a 40 kDa polyethylene glycol fragment, is cleaved off, leaving the native factor IX molecule. Activated factor IX in combination with activated factor VIII activates factor X. Activated factor X converts prothrombin to thrombin. Thrombin then converts fibrinogen to fibrin and a clot is formed.

Active ingredient: Nonacog beta-pegol

Prescription drug

Storage temperature 2-8 degrees